The biological effectiveness of targeted radionuclide therapy based on a whole-body pharmacokinetic model

Physics in Medicine and Biology

Volumn 55, Issue 19, 2010, Pages 5723-5734

  Grudzinski, Joseph J ^a   Tomé, Wolfgang ^a   Weichert, Jamey P ^a   Jeraj, Robert ^a,b  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b JO EF STEFAN INSTITUTE   (Slovenia)

Author keywords

[No Author keywords available]

Indexed keywords

ABSORBED DOSE; ANALYTICAL EQUATIONS; BIOLOGICAL EFFECTIVENESS; BIOLOGICAL EFFECTS; BIOLOGICALLY EFFECTIVE DOSE; DOSE RATE; PHARMACOKINETIC MODEL; REPAIR RATE; TARGETED RADIONUCLIDE THERAPIES; TIME-ACTIVITY CURVES; WHOLE-BODY;

PHARMACOKINETICS; RADIOISOTOPES; REPAIR;

TUMORS;

RADIOISOTOPE;

ARTICLE; BIOLOGICAL MODEL; METABOLISM; NEOPLASM; RELATIVE BIOLOGIC EFFECTIVENESS; REPRODUCIBILITY;

MODELS, BIOLOGICAL; NEOPLASMS; RADIOISOTOPES; RELATIVE BIOLOGICAL EFFECTIVENESS; REPRODUCIBILITY OF RESULTS;

EID: 78249234687     PISSN: 00319155     EISSN: 13616560     Source Type: Journal    
DOI: 10.1088/0031-9155/55/19/007     Document Type: Article

References (41)

1. Aft R L, Lewis J S, Zhang F, Kim J and Welch M J 2003 Enhancing targeted radiotherapy by copper (II) diacetylbis (N-4-methylthiosemicarbazone) using 2-deoxy-D-glucose Cancer Res. 63 5496-504
2. Barone R, Borson-Chazot F, Valkema R, Walrand S, Chauvin F, Gogou L, Kvols L K, Krenning e P, Jamar F and Pauwels S 2005 Patient-specific dosimetry in predicting renal toxicity with (90) Y-DOTATOC: relevance of kidney volume and dose rate in finding a dose-effect relationship J. Nucl. Med. 46 (Suppl. 1) 99S-106S
3. Bodey R K 2004 The combination of dosimetry for targeted radionuclide and external beam therapies Medical Physics (London: The Institute of Cancer Research & Royal Marsden NHS Foundation Trust) p 219
4. Bodey R K, Evans P M and Flux G D 2004 Application of the linear-quadratic model to combined modality radiotherapy Int. J. Radiat. Oncol. Biol. Phys. 59 228-41
5. Bodey R K, Flux G D and Evans P M 2003 Combining dosimetry for targeted radionuclide and external beam therapies using the biologically effective dose Cancer Biother. Radiopharmaceuticals 18 89-97
6. Brenner D J, Hlatky L R, Hahnfeldt P J, Huang y and Sachs R K 1998 The linear-quadratic model and most other common radiobiological models result in similar predictions of time-dose relationships Radiat. Res. 150 83-91
7. Carlsson J, Forssell-Aronsson E, Glimelius B and Mattsson S 2002 Therapy with radiopharmaceuticals Acta Oncol. (Stockholm, Sweden) 41 623-8
8. Chapman J D 2003 Single-hit mechanism of tumour cell killing by radiation Int. J. Radiat. Biol. 79 71-81
9. Dale R and Carabe-Fernandez A 2005 The radiobiology of conventional radiotherapy and its application to radionuclide therapy Cancer Biother. Radiopharmaceuticals 20 47-51
10. Dale R G 1985 The application of the linear-quadratic dose-effect equation to fractionated and protracted radiotherapy Br. J. Radiol. 58 515-28
11. Dale R G 1989 Radiobiological assessment of permanent implants using tumour repopulation factors in the linearquadratic model Br. J. Radiol. 62 241-4
12. Dale R G 1996 Dose-rate effects in targeted radiotherapy Phys. Med. Biol. 41 1871-84
13. DeNardo S J and Denardo G L 2006 Targeted radionuclide therapy for solid tumors: an overview Int. J. Radiat. Oncol. Biol. Phys. 66 S89-95
14. Fowler J F 1990 Radiobiological aspects of low dose rates in radioimmunotherapy Int. J. Radiat. Oncol. Biol. Phys. 18 1261-9
15. Gallo J M, Vicini P, Orlansky A, Li S, Zhou F, Ma J, Pulfer S, Bookman M A and Guo P 2004 Pharmacokinetic model-predicted anticancer drug concentrations in human tumors Clin. Cancer Res. 10 8048-58
16. Grudzinski J J, Burnette R R, Weichert J P and Jeraj R 2010 Dosimetric effectiveness of targeted radionuclide therapy based on a pharmacokinetic landscape Cancer Biother. Radiopharmaceuticals 25 417-26
17. Hall E J and Giaccia A J 2006 Radiobiology for the Radiologist (Philadelphia, PA: Lippincott Williams & Wilkins)
18. Hobbs R F and Sgouros G 2009 Calculation of the biological effective dose for piecewise defined dose-rate fits Med. Phys. 36 904-7
19. Kalogianni E, Flux G D and Malaroda A 2007 The use of BED and EUD concepts in heterogeneous radioactivity distributions on a multicellular scale for targeted radionuclide therapy Cancer Biother. Radiopharmaceuticals 22 143-50
20. Lassmann M, Hanscheid H, Reiners C and Thomas S R 2005 Blood and bone marrow dosimetry in radioiodine therapy of differentiated thyroid cancer after stimulation with rhTSH J. Nucl. Med. 46 900-1 (author reply 1)
21. Lazarescu G R and Battista J J 1997 Analysis of the radiobiology of ytterbium-169 and iodine-125 permanent brachytherapy implants Phys. Med. Biol. 42 1727-36
22. Ma B B, Bristow R G, Kim J and Siu L L 2003 Combined-modality treatment of solid tumors using radiotherapy and molecular targeted agents J. Clin. Oncol. 21 2760-76
23. Millar W T 1991 Application of the linear-quadratic model with incomplete repair to radionuclide directed therapy Br. J. Radiol. 64 242-51
24. O'Donoghue J A 1999 Implications of nonuniform tumor doses for radioimmunotherapy J. Nucl. Med. 40 1337-41
25. Oyen W J, Bodei L, Giammarile F, Maecke H R, Tennvall J, Luster M and Brans B 2007 Targeted therapy in nuclear medicine-current status and future prospects Ann. Oncol. 18 1782-92
26. Pacilio M, Betti M, Cicone F, Del Mastro C, Montani L, Chiacchiararelli L, Monaco A, Santini e and Scopinaro F 2010 A theoretical dose-escalation study based on biological effective dose in radioimmunotherapy with (90) Y-ibritumomab tiuxetan (Zevalin) Eur. J. Nucl. Med. Mol. Imaging 37 862-73
27. Roberson P L and Buchsbaum D J 1995 Reconciliation of tumor dose response to external beam radiotherapy versus radioimmunotherapy with 131iodine-labeled antibody for a colon cancer model Cancer Res. 55 5811s-6s
28. Sachs R K, Hahnfeld P and Brenner D J 1997 The link between low-LET dose-response relations and the underlying kinetics of damage production/repair/misrepair Int. J. Radiat. Biol. 72 351-74
29. Siegel J A 2005 Establishing a clinically meaningful predictive model of hematologic toxicity in nonmyeloablative targeted radiotherapy: practical aspects and limitations of red marrow dosimetry Cancer Biother. Radiopharmaceuticals 20 126-40
30. Strigari L, D'Andrea M, Maini C L, Sciuto R and Benassi M 2006 Biological optimization of heterogeneous dose distributions in systemic radiotherapy Med. Phys. 33 1857-66
31. Thames H and Hendry J 1987 Fractionation in Radiotherapy (London: Taylor & Francis)
32. Thames H D, Ang K K, Stewart F A and Van der Schueren E 1988 Does incomplete repair explain the apparent failure of the basic LQ model to predict spinal cord and kidney responses to low doses per fraction? Int. J. Radiat. Biol. 54 13-9
33. Wagner J G 1975 Fundamentals of Clinical Pharmacokinetics (Hamilton, IL: Drug Intelligence Publications, Inc.)
34. Wagner J G 1993 Pharmacokinetics for the Pharmaceutical Scientist (Lancaster, PA: Technomic Publishing)
35. Wessels B W et al 2008 MIRD Pamphlet No. 20: the effect of model assumptions on kidney dosimetry and response-implications for radionuclide therapy J. Nucl. Med. 49 1884-99
36. Wessels B W and Meares C F 2000 Physical and chemical properties of radionuclide therapy Semin. Radiat. Oncol. 10 115-22
37. Williams L E, DeNardo G L and Meredith R F 2008 Targeted radionuclide therapy Med. Phys. 35 3062-8
38. Yang y and Xing L 2005 Optimization of radiotherapy dose-time fractionation with consideration of tumor specific biology Med. Phys. 32 3666-77
39. Zanzonico P B 2000 Internal radionuclide radiation dosimetry: a review of basic concepts and recent developments J. Nucl. Med. 41 297-308
40. Zeng Z C, Tang Z Y, Yang B H, Liu K D, Wu Z Q, Fan J, Qin L X, Sun H C, Zhou J and Jiang G L 2002 Comparison between radioimmunotherapy and external beam radiation therapy for patients with hepatocellular carcinoma Eur. J. Nucl. Med. Mol. Imaging 29 1657-68
41. Zhu H, Jain R K and Baxter L T 1998 Tumor pretargeting for radioimmunodetection and radioimmunotherapy J. Nucl. Med. 39 65-76